Research highlights potential target for osteoarthritis treatment

Date:

Share this article:

Del denne artikel:

For millions living with stiff and painful joints, new research is quietly reshaping how scientists think about aging and mobility.

Joint pain rarely arrives overnight. It builds slowly through sore mornings, reduced movement, and small adjustments that become habits.

Many people accept these changes as a natural cost of aging, especially when it comes to knees and hips.

New findings from researchers at Stanford University suggest that this decline may not be as inevitable as once thought.

A biological trigger

The research focused on a protein called 15-PGDH, which becomes more active as the body ages.

Also read: How early-life factors may shape colon cancer risk decades later

Scientists have long known that this protein interferes with processes that control inflammation and tissue repair.

The Stanford team examined whether it also plays a central role in osteoarthritis, a condition driven by cartilage breakdown.

In experiments on mice, blocking this protein led to notable changes. Older mice showed signs of cartilage recovery, while younger mice with joint injuries avoided the typical progression toward osteoarthritis.

The results suggested that joint damage linked to aging could be influenced at a molecular level.

Also read: Lumps and swellings: when to seek medical advice

Repairing from within

Rather than introducing stem cells, the treatment appeared to work by reprogramming existing cartilage cells.

These cells shifted into a healthier state, allowing them to rebuild tissue and reduce inflammation.

The physical impact was measurable. Treated animals moved more evenly and placed less strain on injured joints, indicating that structural improvements translated into better function.

Implications for patients

The team also tested the approach on human cartilage obtained during knee replacement surgeries.

Also read: Genetic predisposition to blood sugar spikes may increase Alzheimer’s risk by 69 percent

The tissue showed increased stiffness and fewer inflammatory markers, pointing to a shared mechanism between mice and humans.

Osteoarthritis currently has no cure, and treatment focuses on pain relief or surgery. While clinical trials are still ahead, earlier safety studies of related drugs may speed development. If successful, this work could reshape how joint aging is treated.

Sources: Science

Also read: Lifelong alcohol consumption increases the risk of colorectal cancer

Also read: How to find the healthiest frozen ready-made meals

This article is made and published by Mie Hermansen, who may have used AI in the preparation.

Other articles

Scientists find a hidden immune pathway that could open new treatments for the deadliest lung cancer

The deadliest lung cancer has slipped past the body's defenses for decades, and researchers now think they have found a way in.

How eating dark chocolate every day may affect your heart, blood pressure and brain

A daily square after dinner feels like a guilty pleasure, but the research behind that small habit tells a more interesting story.

How eating oats every day could quietly lower your LDL cholesterol

A small daily amount of one everyday grain carries a rare regulator's stamp of approval, and newer trials keep backing it up.

The five-letter home check that catches most melanomas, and where AI now helps

Mole-mapping tools are moving into clinics, but what you notice in your own mirror is still the earliest warning.

Scientists find a hidden immune pathway that could open new treatments for the deadliest lung cancer

The deadliest lung cancer has slipped past the body's defenses for decades, and researchers now think they have found a way in.

How eating dark chocolate every day may affect your heart, blood pressure and brain

A daily square after dinner feels like a guilty pleasure, but the research behind that small habit tells a more interesting story.

How eating oats every day could quietly lower your LDL cholesterol

A small daily amount of one everyday grain carries a rare regulator's stamp of approval, and newer trials keep backing it up.